{"id":"https://openalex.org/W2018962392","doi":"https://doi.org/10.2147/blctt.s29567","title":"Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies","display_name":"Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies","publication_year":2013,"publication_date":"2013-04-01","ids":{"openalex":"https://openalex.org/W2018962392","doi":"https://doi.org/10.2147/blctt.s29567","mag":"2018962392"},"language":"en","primary_location":{"id":"doi:10.2147/blctt.s29567","doi":"https://doi.org/10.2147/blctt.s29567","is_oa":true,"landing_page_url":"https://doi.org/10.2147/blctt.s29567","pdf_url":"https://www.dovepress.com/getfile.php?fileID=15836","source":{"id":"https://openalex.org/S4210230819","display_name":"Blood and Lymphatic Cancer Targets and Therapy","issn_l":"1179-9889","issn":["1179-9889"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood and Lymphatic Cancer: Targets and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=15836","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009336240","display_name":"Daryl Chen Lung Tan","orcid":"https://orcid.org/0000-0003-2430-3308","observed_orcids":["https://orcid.org/0000-0003-2430-3308"]},"institutions":[{"id":"https://openalex.org/I2251586001","display_name":"Singapore General Hospital","ror":"https://ror.org/036j6sg82","country_code":"SG","type":"healthcare","lineage":["https://openalex.org/I2251586001"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Daryl Tan","raw_affiliation_strings":["Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore","Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore","institution_ids":["https://openalex.org/I2251586001"]},{"raw_affiliation_string":"Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109289968","display_name":"Sathish Krishnan","orcid":"https://orcid.org/0009-0005-3321-0914","observed_orcids":["https://orcid.org/0009-0005-3321-0914"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sathish Krishnan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2320,"currency":"USD","value_usd":2320},"apc_paid":{"value":2320,"currency":"USD","value_usd":2320},"fwci":0.213,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.58053248,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":"19","last_page":"19"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":1.0},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/cd38","display_name":"CD38","score":0.906000018119812},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9179999828338623},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9100000262260437},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.6629999876022339},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9539999961853027},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.8799999952316284},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6100000143051147},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6579999923706055},{"id":"https://openalex.org/keywords/mechanism-of-action","display_name":"mechanism of action","score":0.7730000019073486}],"concepts":[{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.9565795063972473},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8378325700759888},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.8116769194602966},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7461828589439392},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6964157819747925},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.597335159778595},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47957271337509155},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.43868210911750793},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38443291187286377},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.355571448802948}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.2147/blctt.s29567","doi":"https://doi.org/10.2147/blctt.s29567","is_oa":true,"landing_page_url":"https://doi.org/10.2147/blctt.s29567","pdf_url":"https://www.dovepress.com/getfile.php?fileID=15836","source":{"id":"https://openalex.org/S4210230819","display_name":"Blood and Lymphatic Cancer Targets and Therapy","issn_l":"1179-9889","issn":["1179-9889"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood and Lymphatic Cancer: Targets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:73f7face19004ee9bc6bb0fa042fbaf2","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Blood and Lymphatic Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 19-24 (2013)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/12811","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/daratumumab-improves-the-anti-myeloma-effect-of-newly-emerging-multidr-peer-reviewed-article-BLCTT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Review"}],"best_oa_location":{"id":"doi:10.2147/blctt.s29567","doi":"https://doi.org/10.2147/blctt.s29567","is_oa":true,"landing_page_url":"https://doi.org/10.2147/blctt.s29567","pdf_url":"https://www.dovepress.com/getfile.php?fileID=15836","source":{"id":"https://openalex.org/S4210230819","display_name":"Blood and Lymphatic Cancer Targets and Therapy","issn_l":"1179-9889","issn":["1179-9889"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood and Lymphatic Cancer: Targets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2018962392.pdf","grobid_xml":"https://content.openalex.org/works/W2018962392.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W83009012","https://openalex.org/W1553619844","https://openalex.org/W1599670023","https://openalex.org/W1965205681","https://openalex.org/W1967198288","https://openalex.org/W1987009989","https://openalex.org/W1994013901","https://openalex.org/W2000130439","https://openalex.org/W2010658521","https://openalex.org/W2021488008","https://openalex.org/W2025970634","https://openalex.org/W2029780627","https://openalex.org/W2057660602","https://openalex.org/W2067489645","https://openalex.org/W2096207943","https://openalex.org/W2101576302","https://openalex.org/W2102942531","https://openalex.org/W2110466835","https://openalex.org/W2117887415","https://openalex.org/W2141502099","https://openalex.org/W2143860449","https://openalex.org/W2231156824","https://openalex.org/W2234907176","https://openalex.org/W2441490494","https://openalex.org/W2465279208","https://openalex.org/W2524057378","https://openalex.org/W2558053580","https://openalex.org/W2560198143","https://openalex.org/W2581159256","https://openalex.org/W2753976862","https://openalex.org/W2969538297","https://openalex.org/W4234971900","https://openalex.org/W4296241157"],"related_works":["https://openalex.org/W2584309972","https://openalex.org/W2565294276","https://openalex.org/W2608137803","https://openalex.org/W1994013901","https://openalex.org/W1967198288","https://openalex.org/W2010232494","https://openalex.org/W2331857836","https://openalex.org/W2997956935","https://openalex.org/W2558724377","https://openalex.org/W2227361765"],"abstract_inverted_index":{"Abstract:":[0],"Although":[1],"the":[2,14,25],"clinical":[3],"outcomes":[4],"of":[5,16,41,106,114],"patients":[6,30],"with":[7,13,100,110],"multiple":[8],"myeloma":[9],"has":[10,79,95],"improved":[11],"tremendously":[12],"advent":[15],"bortezomib":[17],"and":[18,23,29,87,102,118],"immunomodulatory":[19],"drugs":[20],"like":[21],"thalidomide":[22],"lenalidomide,":[24],"disease":[26],"remains":[27],"incurable":[28],"will":[31,121],"eventually":[32],"be":[33,122],"resistant":[34],"to":[35],"these":[36],"drugs.":[37],"Novel":[38],"non-cross-resistant":[39],"modalities":[40],"treatment":[42],"are":[43],"needed.":[44],"Immunotherapy":[45],"is":[46,57],"potentially":[47],"a":[48,58,66,81],"very":[49],"promising":[50],"therapeutic":[51,61],"modality":[52],"for":[53],"further":[54],"development.":[55],"Daratumumab":[56],"novel,":[59],"high-affinity,":[60],"human":[62],"monoclonal":[63,130],"antibody":[64],"against":[65],"unique":[67],"CD38":[68],"epitope.":[69],"It":[70,78,94],"induces":[71],"tumor-cell":[72],"killing":[73],"through":[74],"several":[75],"immunological":[76],"mechanisms.":[77],"shown":[80],"favorable":[82],"safety":[83,119],"profile":[84],"as":[85],"monotherapy":[86],"significant":[88],"single-agent":[89],"activity":[90],"in":[91,124],"relapsed/refractory":[92],"myeloma.":[93],"also":[96],"demonstrated":[97],"strong":[98],"synergism":[99],"lenalidomide":[101],"bortezomib.":[103],"The":[104],"potential":[105],"this":[107,125],"agent,":[108],"together":[109],"its":[111],"pharmacokinetics,":[112],"mode":[113],"action,":[115],"early":[116],"efficacy,":[117],"data":[120],"detailed":[123],"review.":[126],"Keywords:":[127],"daratumumab,":[128],"myeloma,":[129]},"counts_by_year":[{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}